Figure 4. Pharmacokinetic profile of KU-32 uptake in plasma and brain after intraperitoneal administration.
(a) KU-32 (2 mg/ml) was injected intraperitoneally in 5% Captisol, and plasma and brain samples were taken at the indicated time. KU-32 levels were quantified by LC-MS. Plasma AUC0-∞, 27.4 μg/min per ml. Results are the means±S.E.M. for six mice per time point. (b) Effect of KU-32 on expression of Hsp70 in sciatic nerve. Mice were injected with KU-32 and sciatic nerve was harvested after 1 week. Hsp70 and β-actin levels were determined by immunoblotting. The level of Hsp70 was normalized to β-actin, and KU-32 increased Hsp70 expression by 1.2- and 1.35-fold at 2 and 20 mg/kg respectively.